A 60 years old nondiabetic woman was referred to our neuromuscular clinic for evaluation of peripheral neuropathy. At age 20, she first noticed patchy brown discolorations and thickening of skin over her armpits and neck ([Fig. 1](#f1){ref-type="fig"}), attributed to birth control use. Shortly thereafter her voice became raspy, and while abroad at age 42, she experienced painful joints and dull ache in the balls of her feet. She was diagnosed by a rheumatologist with Fibromyalgia and prescribed methotrexate and NSAIDs with some relief for 3 years. Also, she observed occasional foaming of her urine and had been told her creatinine was mildly elevated, and that renal biopsy had revealed tubulointerstitial disease, but was negative for amyloid. At age 46, her Creatinine was 1.5 mg/dl \[normal range 0.6--1.1 mg/dl\], and subsequently remained stable \~1.3 mg/dl over the past 20 years followed by nephrology. At age 48, she presented for palpitations due to supra ventricular tachycardia and experienced chronic fatigue, dyspnea on exertion and pedal edema, ultimately underwent an ablation at age 49 and placement of pacemaker at age 60.

![brown discoloration and thickening of patient's left armpit (**A**) and neck (**B**).](omaa014f1){#f1}

Her family history was significant for genetically confirmed hereditary apolipoprotein A-1 amyloidosis with raspy voices and skin changes in her father, paternal grandmother and aunt and her three sisters. Genotyping for a transthyretin (TTR) mutation was negative. A biopsy of an axillary discolored skin revealed amyloid deposits on Congo red. Genetic testing was positive for Arg173Pro mutation, confirming apolipoprotein A-1 amyloidosis, a systemic disease with considerable clinical variation associated with cutaneous, cardiac, neurologic and gastrointestinal involvement as well as renal failure \[[@ref1]\].

This patient exemplifies the prolonged and difficult journey many patients endure despite an impressive family history. Ultimately, her unique skin manifestation have raised our suspicion of apolipoprotein A-1, leading to the final diagnosis.
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